A Phase 3 interventional study of Sitagliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 57th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14,671 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one has the largest enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 86 in phase 3, and was the 64th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%.
Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
Drug: Sitagliptin
Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
Drug: Placebo
Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
Also known as: MK-0431, Januvia®
Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.
Time frame: Up to 5 years
Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.
Time frame: Up to 5 years
Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.
Time frame: Up to 5 years
Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.
Time frame: Up to 5 years
Percent Incidence of All-cause Mortality (Per Protocol Population)
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.
Time frame: Up to 5 years
Percent Incidence of All-cause Mortality (Intent to Treat Population)
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.
Time frame: Up to 5 years
Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.
Time frame: Up to 5 years
Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.
Time frame: Up to 5 years
Change From Baseline in Renal Function Over Time (Per Protocol Population)
Change in renal function based on estimated glomerular filtration rate \[eGFR\] using the Modification of Diet in Renal Disease \[MDRD\] method.
Time frame: Baseline and up to 5 years
Change From Baseline in Renal Function Over Time (Intent to Treat Population)
Change in renal function based on eGFR using the MDRD method.
Time frame: Baseline and up to 5 years
Change From Baseline in HbA1c Over Time (Per Protocol Population)
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.
Time frame: Baseline and up to 4 years
Change From Baseline in HbA1c Over Time (Intent to Treat Population)
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.
Time frame: Baseline and up to 4 years
Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.
Time frame: Baseline and up to 5 years
Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.
Time frame: Baseline and up to 5 years
Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.
Time frame: Up to 5 years
Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.
Time frame: Up to 5 years
Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent \[AHA\] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)
Time frame: Up to 5 years
Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)
Time frame: Up to 5 years
| Milestone | Sitagliptin | Placebo |
|---|---|---|
| Started | 7332 | 7339 |
| Treated | 7266 | 7274 |
| Completed | 6972 | 6905 |
| Not completed | 360 | 434 |
| Withdrew: Lost to follow-up | 61 | 71 |
| Withdrew: Withdrawal by subject | 299 | 363 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population) | 9.6 | 9.6 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population) | 11.4 | 11.6 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population) | 8.4 | 8.3 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population) | 10.2 | 10.2 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percent Incidence of All-cause Mortality (Per Protocol Population) | 4.7 | 4.3 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percent Incidence of All-cause Mortality (Intent to Treat Population) | 7.5 | 7.3 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population) | 2.8 (1.00 to 1.53) | 2.8 (0.84 to 1.33) |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population) | 3.1 (1.00 to 1.53) | 3.1 (0.84 to 1.33) |
Change in renal function based on estimated glomerular filtration rate \[eGFR\] using the Modification of Diet in Renal Disease \[MDRD\] method.
| mL/min/1.73 m^2 | Sitagliptin | Placebo |
|---|---|---|
| Month 4; Sitagliptin, n= 3859; Placebo, n= 3864 | -1.9 ± 14.2 | -0.8 ± 14.3 |
| Month 8; Sitagliptin, n= 3562; Placebo, n= 3501 | -2.5 ± 14.9 | -0.9 ± 15.1 |
| Month 12; Sitagliptin, n=4912, Placebo, n=4778 | -1.8 ± 15.8 | -0.5 ± 16.2 |
| Month 24; Sitagliptin, n=4782, Placebo, n=4637 | -3.1 ± 17.9 | -1.7 ± 17.5 |
| Month 36; Sitagliptin, n=2776, Placebo, n=2614 | -3.7 ± 18.0 | -1.6 ± 18.8 |
| Month 48; Sitagliptin, n=1096, Placebo, n=1056 | -3.7 ± 18.3 | -2.8 ± 18.4 |
| Month 60; Sitagliptin, n=79, Placebo, n=88 | -3.5 ± 18.2 | -6.4 ± 17.3 |
Change in renal function based on eGFR using the MDRD method.
| mL/min/1.73 m^2 | Sitagliptin | Placebo |
|---|---|---|
| Month 4; Sitagliptin, n=3949; Placebo, n=3977 | -1.8 ± 14.3 | -0.8 ± 14.3 |
| Month 8; Sitagliptin, n=3687; Placebo, n=3648 | -2.4 ± 14.8 | -0.9 ± 15.2 |
| Month 12; Sitagliptin, n=5082; Placebo, n=5015 | -1.8 ± 15.8 | -0.5 ± 16.3 |
| Month 24; Sitagliptin, n=5157; Placebo, n=5071 | -3.2 ± 17.9 | -1.7 ± 17.7 |
| Month 36; Sitagliptin, n=3037; Placebo, n=2942 | -3.8 ± 18.1 | -1.6 ± 18.7 |
| Month 48; Sitagliptin, n=1237; Placebo, n=1210 | -4.0 ± 18.4 | -2.8 ± 18.3 |
| Month 60; Sitagliptin, n=93; Placebo, n=106 | -4.2 ± 17.4 | -5.7 ± 17.2 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.
| Percentage of HbA1c | Sitagliptin | Placebo |
|---|---|---|
| Month 4; Sitagliptin, n=6632, Placebo, n=6588 | -0.3 ± 0.8 | 0.1 ± 0.9 |
| Month 8; Sitagliptin, n=6294, Placebo, n=6197 | -0.3 ± 0.9 | 0.1 ± 1.0 |
| Month 12; Sitagliptin, n=6217, Placebo, n=6092 | -0.2 ± 1.0 | 0.1 ± 1.0 |
| Month 24; Sitagliptin, n=5668, Placebo, n=5475 | -0.1 ± 1.0 | 0.2 ± 1.1 |
| Month 36; Sitagliptin, n=3227, Placebo, n=3083 | -0.1 ± 1.1 | 0.1 ± 1.1 |
| Month 48; Sitagliptin, n=1271, Placebo, n=1224 | 0.0 ± 1.1 | 0.1 ± 1.2 |
| Month 60; Sitagliptin, n=106, Placebo, n=108 | -0.1 ± 1.0 | 0.0 ± 0.9 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.
| Percentage of HbA1c | Sitagliptin | Placebo |
|---|---|---|
| Month 4: Sitagliptin, n= 6772; Placebo, n= 6738 | -0.3 ± 0.8 | 0.1 ± 0.9 |
| Month 8: Sitagliptin, n= 6478; Placebo, n= 6414 | -0.2 ± 0.9 | 0.1 ± 1.0 |
| Month 12: Sitagliptin, n= 6448; Placebo, n= 6384 | -0.2 ± 1.0 | 0.1 ± 1.0 |
| Month 24: Sitagliptin, n= 6105; Placebo, n= 5975 | -0.1 ± 1.0 | 0.1 ± 1.1 |
| Month 36: Sitagliptin, n= 3521; Placebo, n= 3439 | -0.1 ± 1.1 | 0.1 ± 1.1 |
| Month 48: Sitagliptin, n= 1432; Placebo, n= 1383 | 0.0 ± 1.1 | 0.1 ± 1.2 |
| Month 60: Sitagliptin, n= 123; Placebo, n= 128 | 0.0 ± 1.0 | 0.0 ± 1.0 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.
| g/mol Creatinine | Sitagliptin | Placebo |
|---|---|---|
| Month 4; Sitagliptin, n=664; Placebo, n=688 | -2.2 ± 27.7 | -1.4 ± 24.6 |
| Month 8; Sitagliptin, n=635; Placebo, n=597 | 1.7 ± 38.5 | 0.2 ± 45.3 |
| Month 12; Sitagliptin, n=1126; Placebo, n=1059 | 0.8 ± 27.7 | 1.2 ± 33.1 |
| Month 24; Sitagliptin, n=930; Placebo, n=892 | 0.7 ± 34.0 | 3.2 ± 31.6 |
| Month 36; Sitagliptin, n=488; Placebo, n=513 | 2.5 ± 24.0 | 4.0 ± 31.0 |
| Month 48; Sitagliptin, n=238; Placebo, n=233 | 1.3 ± 15.2 | 1.5 ± 25.5 |
| Month 60; Sitagliptin, n=13; Placebo, n=17 | -2.7 ± 10.1 | 4.8 ± 15.4 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.
| g/mol Creatinine | Sitagliptin | Placebo |
|---|---|---|
| Month 4; n=677, n=713 | -2.1 ± 27.5 | -1.4 ± 24.1 |
| Month 8; n=658, n=624 | 2.1 ± 39.4 | 0.5 ± 44.5 |
| Month 12; n=1167, n=1115 | 1.3 ± 30.2 | 1.2 ± 32.3 |
| Month 24; n=1011, n=964 | 0.5 ± 33.1 | 3.1 ± 30.7 |
| Month 36; n=537, n=553 | 2.6 ± 25.8 | 3.9 ± 30.3 |
| Month 48; n=265, n=256 | 1.9 ± 16.3 | 1.6 ± 24.5 |
| Month 60; n=14, n=18 | -2.5 ± 9.7 | 6.4 ± 16.4 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population) | 8.6 | 11.9 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population) | 9.7 | 13.2 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent \[AHA\] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population) | 18.9 | 24.5 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population) | 21.7 | 27.9 |
Collected over Up to 68 months (including up to 28 days after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 928/7,266 (12.8%) | 0/7,266 (0%) |
| Placebo | — | 909/7,274 (12.5%) | 0/7,274 (0%) |
| Event | Sitagliptin | Placebo |
|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 44/7266 | 55/7274 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 52/7266 | 35/7274 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 36/7266 | 45/7274 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 26/7266 | 38/7274 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 13/7266 | 30/7274 |
| Non-cardiac chest painGeneral disorders | 17/7266 | 26/7274 |
| AnaemiaBlood and lymphatic system disorders | 23/7266 | 23/7274 |
| HyponatraemiaMetabolism and nutrition disorders | 8/7266 | 21/7274 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 12/7266 | 20/7274 |
| Accidental overdoseInjury, poisoning and procedural complications | 17/7266 | 19/7274 |
| Age, Customized(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Adults 18 - 64 years | 3315 ± 7.9 | 3301 ± 8.0 | 65.5 ± 8.0 |
| From 65 - 84 years | 3813 | 3821 | 7634 |
| 85 years and over | 46 | 55 | 101 |
| Unknown age | 158 | 162 | 320 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Female | 2134 | 2163 | 4297 |
| Male | 5198 | 5176 | 10374 |
| Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73 m^2) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 74.9 ± 21.3 | 74.9 ± 20.9 | 74.9 ± 21.1 |
| Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 7.2 ± 0.5 | 7.2 ± 0.5 | 7.2 ± 0.5 |
| Urine albumin creatinine ratio(g/mol Creatinine) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 8.6 ± 37.4 | 8.4 ± 36.0 | 8.5 ± 36.7 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2008 to primary completion in Mar 2015, 75 months.
Results were first posted in Apr 2016, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 75 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin